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Abstract
Background: Screening for hepatitis B virus (HBV) infection is recommended worldwide for patients receiving
systemic chemotherapy in accordance with clinical guidelines, but compliance varies by country and facility.
Alert systems may be useful for promoting screening, but it is unclear how effective such systems are. In this study,
we investigated HBV screening procedures and their incorporation into treatment regimens following the
implementation of an alert system.
Methods: An alert system was introduced at our hospital in April 2012. The rates of HBV screening in the periods
before and after the introduction of the alert system (September 2010 to March 2012 and April 2012 to October
2013, respectively) were investigated. We collected data on hepatitis B surface antigen (HBsAg), hepatitis B surface
antibody (HBsAb), hepatitis B core antibody (HBcAb), and HBV-DNA testing in patients. As a result of this analysis,
we developed a system in which pharmacists would intervene to check and confirm whether HBV screening had
occurred in patients scheduled to begin treatment with chemotherapy. We named our project the “HBView”
project, and the rate of HBV screening and the number of times pharmacists intervened was studied during specific
time periods before and after the HBView project commenced (July 2013 to December 2013 and January 2014 to
June 2014, respectively).
Results: After introducing the alert system, the percentage of patients tested for HBsAb/HBcAb and HBV-DNA
increased significantly, from 71.6 % to 84.9 % and from 44.5 % to 69.7 %, respectively. However, the rate of
compliance with HBV testing guidelines was not 100 % after interventions. The numbers of patients who were
not screened but should have been before and after the introduction of HBView were 6 and 17, respectively.
Two patients at risk of HBV reactivation were identified after intervention by pharmacists; their intervention thus
prevented HBV reactivation.
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Conclusions: Compliance with clinical HBV screening guidelines was not sufficiently improved after the
introduction of the automatic alert system; however, the HBView project proved useful in reinforcing the automatic
alert system.
Keywords: HBV reactivation, Cancer chemotherapy, Computer-assist system, Pharmacist intervention
Background
In recent years, many cytotoxic and molecular-targeted
anti-cancer drugs have been developed, increasing the
complexity of chemotherapy indications and regimens.
These antineoplastic agents have strong pharmacological
activity, and fatal adverse events are possible if medical
personnel do not follow prescription guidelines carefully.
Hepatitis B virus (HBV) reactivation is thought to be
one of the harmful adverse events that can arise during
cancer chemotherapy. When HBV reactivation occurs,
treatment of the underlying disease becomes difficult
and can sometimes be fatal. Treatment with a combin-
ation of rituximab and corticosteroids, for example, is
one of the risk factors for HBV reactivation. Hence, it is
necessary to take precautions to avoid HBV reactivation
in patients receiving chemotherapy [1].
The onset rate of fulminant hepatitis in HBV-
reactivated patients is higher than that of acute hepatitis,
according to a research study in Japan. Additionally, a
study reported that the death rate in patients with ful-
minant hepatitis due to HBV reactivation was 100 % [2].
The “Guideline for the Prevention of Immunosuppres-
sive Therapy or Chemotherapy-induced Reactivation of
Hepatitis B Virus Infection” was released in Japan in
2009 [3, 4]. The contents of this guideline have since
been incorporated into the Japan Society of Hepatology
(JHS)’s “JSH Guidelines for the Management of Hepatitis
B Virus Infection” [5]. The guidelines recommend
screening all patients receiving immunosuppression and
systemic chemotherapy for HBV. This recommendation
is also included in guidelines recently introduced
overseas, such as those by the American Association for
the Study of Liver Disease [6] and the European Associ-
ation for the Study of the Liver [7].
However, the importance of HBV screening is not
widely understood in many countries, including Japan.
Various measures have been adopted to solve this prob-
lem [8–10]. In recent years, HBV reactivation rates using
computer-assist systems have been reported, and aware-
ness of the issue has improved the rate of screening
guideline enforcement [11–13]. Evaluating the sequelae
of HBV reactivation is confounded by the sheer number
of clinical departments, the use of multiple immunosup-
pressant and antineoplastic agents, and the diversity of
the patients’ conditions. Alert systems are considered an
effective measure to counter this problem. An alert
system for HBV reactivation was introduced at our hos-
pital in April 2012, according to which an alert message
that requests an HBV inspection is displayed upon entry
of a prescription for a chemotherapy regimen, followed
by the automatic appearance of the inspection ordering
screen. However, we hypothesized that lapses in HBV
testing occur despite this alert system.
Hence, we launched a study to determine the rate of
compliance with HBV testing recommendations. We
named this intervention the “HBView project”, and we
herein report the outcome of introducing this alert sys-
tem at our hospital.
Methods
Alert system for HBV reactivation associated with cancer
chemotherapy
An alert system for HBV testing that is linked to
computerized chemotherapy regimen ordering was in-
troduced in April 2012. The displayed message recom-
mends inspections according to the JSH Guidelines for
the Management of Hepatitis B Virus Infection [5]. The
computer alert message displayed when a new regimen
is ordered is shown in Fig. 1. When "Yes" is chosen
under the first alert message, a screen from which doc-
tors can order the laboratory test for hepatitis B surface
antibody (HBsAb) and hepatitis B core antibody
(HBcAb) (using the chemiluminescence enzyme im-
munoassay method) appears automatically. When a
second cycle regimen is ordered, a second alert message
(Fig. 1) is displayed. When "Yes" is chosen, the screen
from which doctors can order a laboratory test for
HBV-DNA (using the real-time quantitative PCR
method) appears automatically. Additionally, the
“Guideline for the Prevention of Immunosuppressive
Therapy or Chemotherapy-induced Reactivation of
Hepatitis B Virus Infection” was available for physicians
to view on the electronic medical record at the time
that this alert system was introduced. The information
in the alert system is revised in accordance with any re-
visions in the guideline.
HBView project
The HBView project was initiated in January 2014 at our
hospital pharmacy to prevent HBV reactivation. The
schema of the measures taken to prevent HBV reactiva-
tion is shown in Fig. 2. The purpose of the project was
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to investigate why patients eluded HBV screening and
why that fact sometimes went unnoticed.
We reviewed hepatitis B surface antigen (HBsAg),
HBsAb, HBcAb, and HBV-DNA test results as well as
the corresponding patients’ histories and the number of
regimen cycles that they underwent. We inquired with
the attending physician if the HBV screening test was
not ordered according to the JSH Guidelines for the
Management of Hepatitis B Virus Infection [5] at the
time the chemotherapy regimen was ordered.
Study design and ethics statement
This study was retrospective, and data regarding the
basic characteristics, cancer type, chemotherapy regi-
men, and status of HBV infection for all patients under-
going chemotherapy were collected; physician and
pharmacist charts were also reviewed. The study was ap-
proved by the Ethics Committee and the Institutional
Review Board of the Nagoya City University Hospital
(No. 1004).
Data on HBsAg, HBsAb, HBcAb, and HBV-DNA in
patients who had been prescribed new regimens prior to
the introduction of the alert system (September 2010 to
March 2012) and afterwards (April 2012 to October
2013) were collected. The inspection rates of HBsAb
and/or HBcAb and HBV-DNA according to the JSH
Guidelines for the Management of Hepatitis B Virus In-
fection [5] were determined.
We also performed a retrospective investigation of
pharmacists’ interventions in patients who were pre-
scribed regimens prior to the start of the HBView
project (July 2013 to December 2013) and after it com-
menced (January 2014 to June 2014) using electronic
medical records. In addition, data on HBsAg, HBsAb,
HBcAb, and HBV-DNA in patients who had been pre-
scribed new regimens prior to start of the HBView pro-
ject (July 2013 to December 2013) and afterwards
(January 2014 to June 2014) were reviewed.
Statistical analysis
Results are expressed as the mean ± standard deviation
or as numbers and percentages. Categorical variables
were compared by Fisher’s exact test or the chi-squared
test, and the means of two groups were compared using
Fig. 1 Flowchart illustrating the hepatitis B virus (HBV) screening
alert system. HBsAb, hepatitis B surface antibody; HBsAg, hepatitis B
surface antigen; HBcAb, hepatitis B core antibody
Fig. 2 Diagram summarizing the alert system and the HBView project. HBV, hepatitis B virus
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the unpaired t-test. Significance was set at P < 0.05. Stat-
istical analysis was performed with R (The R Foundation
for Statistical Computing, version 3.1.1) [14].
Results
Patient characteristics
The number of patients who were prescribed new regi-
mens was 880 and 926 before and after the alert system
was established, respectively. There was no significant
difference in patient characteristics between the two
groups (Table 1).
Compliance with HBV screening guidelines with the alert
system
As shown in Fig. 3, the screening rates for HBsAg, HBsAb
and/or HBcAb, and HBV-DNA were 98.0 % (862/880),
71.6 % (621/834), and 44.5 % (61/137), respectively, before
the introduction of the alert system. After introducing the
alert system, the screening rates for HBsAg, HBsAb and/
or HBcAb, and HBV-DNA were 99.0 % (917/926), 84.9 %
(777/899), and 69.7 % (124/178) respectively. There was
no significant difference in screening rates for HBsAg be-
fore and after the alert system was initiated (P = 0.060)
(Fig. 3a). However, the screening rates for HBsAb, HBcAb,
and HBV-DNA after the introduction of the alert system
increased compared to the rates prior to its introduction
(P < 0.001) (Fig. 3b, c).
Pharmacist intervention concerning HBV reactivation
The number of patients who were prescribed new regi-
mens was 294 and 340 before and after the HBView
project was established, respectively. There was no sig-
nificant difference in patient characteristics between the
two groups (data not shown). As shown in Fig. 4, the
screening rates for HBsAg, HBsAb and/or HBcAb, and
HBV-DNA were 99.0 % (291/294), 90.6 % (260/287), and
69.1 % (47/68) respectively, before the start of the
HBView project. After the start of the HBView project,
the screening rates for HBsAg, HBsAb and/or HBcAb,
and HBV-DNA were 98.2 % (334/340), 93.6 % (307/329),
and 72.4 % (42/58), respectively. The number of regi-
mens reviewed by pharmacists was 5208 and 5228 be-
fore and after the initiation of the HBView project,
respectively. Pharmacists intervened six times in patient
cases before the HBView project was initiated; however,
the number of interventions increased to 17 after the
project commenced (P = 0.022).
Pharmacists had not exposed any incidents of ser-
ious oversight prior to the HBView project. However,
two cases were exposed after the project was initiated
(Table 2). One was a 58-year-old woman with cervical
cancer who was to undergo surgery concomitant with
radiotherapy and CDDP (cisplatin 40 mg/m2/2 h)
4 days later. In reviewing the regimen, a pharmacist
noticed that her HBsAg and HBV-DNA levels were
unknown even though her HBsAb and HBcAb tests
were positive. The pharmacist informed the attending
physician, and an HBV-DNA test was ordered. The
test revealed a high copy number of HBV-DNA (7.4
log copies/mL). The attending physician immediately
consulted a hepatologist, and nucleic acid analog
treatment was started. Levels of alanine transaminase
and aspartate transaminase increased temporarily, but
there was no HBV reactivation. HBV-DNA levels grad-
ually subsided.
The other patient was a 72-year-old man with colorectal
cancer who had undergone partial hepatectomy 4 years
previously. HBsAg was positive before surgery; however, he
had been receiving mFOLFOX6 (oxaliplatin 85 mg/m2/2 h,
levofolinate 200 mg/m2/2 h, and fluorouracil 400 mg/m2
bolus + 2400 mg/m2/46 h), bevacizumab (5 mg/kg) +
mFOLFOX6, and bevacizumab + FOLFIRI (irinotecan
150 mg/m2/1.5 h, levofolinate 200 mg/m2/2 h, and fluoro-
uracil 400 mg/m2 bolus + 2400 mg/m2/46 h) without pre-
ventive treatment with a nucleic acid analog. Fortunately,
the patient had not experienced HBV reactivation. After
Table 1 Patient characteristics in the groups studied before and after alert system implementation
Pre-alert system Post-alert system P-value Analysis
(n = 880) (n = 926)
Age (years; mean ± SD) 62.0 ± 13.8 62.3 ± 15.3 0.137 (1)
Sex (male/female) 465/415 488/438 0.952 (2)
Cancer type (number, %)
Breast cancer 119 (13.5) 124 (13.4) 0.99 (2)
Lung cancer 129 (14.7) 141 (15.2) 0.785 (2)
Gastric cancer 43 (4.9) 36 (3.9) 0.356 (2)
Colorectal cancer 59 (6.7) 61 (6.6) 0.996 (2)
Hematopoietic malignancy 151 (17.2) 184 (19.9) 0.155 (2)
Others 379 (43.1) 380 (41.0) 0.409 (2)
(1) Unpaired t-test, (2) Chi-squared test. SD, standard deviation
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commencement of the HBView project, a pharmacist
noticed that this patient had tested positive for HBV-
DNA 1 year previously. The pharmacist suggested that
the attending physician consult a hepatologist. HBV-
DNA positivity was confirmed; yet, the attending phys-
ician took no action. Two months later, another
pharmacist noticed the patient’s HBV-DNA positive
status and informed the attending physician again. A
nucleic acid analog was administered to the patient,
after which HBV-DNA gradually decreased.
Discussion
In recent years, HBV reactivation in cancer chemother-
apy has attracted more attention, and there have been
reports of certain measures being implemented to ad-
dress this problem [11–13, 15]. For example, a system
Fig. 3 Screening rates of hepatitis B virus (HBV) before and after introducing the alert system. a) represents HBsAg test. b) represents HBsAb and/
or HBcAb test. c) represents HBV-DNA test. HBsAb, hepatitis B surface antibody; HBsAg, hepatitis B surface antigen; HBcAb, hepatitis B core anti-
body, NS: not significant, ***P < 0.001 (Chi-squared test)
Fig. 4 Screening rates of hepatitis B virus (HBV) before and after the start of the HBView project. a) represent HBsAg test. b) represents HBsAb
and/or HBcAb test. c) represents HBV-DNA test. HBsAb, hepatitis B surface antibody; HBsAg, hepatitis B surface antigen; HBcAb, hepatitis B core
antibody, NS: not significant (Chi-squared test)
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was designed to encode the status of patients receiving
immunosuppressive therapy and/or chemotherapy, in
which the system automatically checks to determine if
the patient has undergone the required tests and treat-
ments according to the practical guidelines for hepatitis
B and reports the results to the primary physician [15].
Additionally, there have been other anti-HBV reactiva-
tion measures that utilize alert systems in Japan and
other countries [11–13]. In this investigation, we evalu-
ated the alert system at our hospital, and found that it
greatly improved the inspection rates of HBsAb and/or
HBcAb, as well as of HBV-DNA, according to the JSH
Guidelines for the Management of Hepatitis B Virus In-
fection [5]. The alert system was very effective in helping
physicians in multiple clinical departments to recognize
the need for such inspections, although enforcement
was not perfect. While the automated alert system is
very useful for risk management, it may be insufficient
for ensuring screening compliance. Therefore, we initi-
ated the HBView project. The HBView project did not
significantly improve compliance with HBV screening
(Fig. 4). There are some possible causes for this. The ini-
tial alert system already had greatly improved compli-
ance with HBV screening, which may have contributed
most to the HBView project’s non-significant results.
We determined that intervention with further compel-
ling force was necessary to improve the compliance rate
for HBV screening.
While there were no significant differences in patient
characteristics before and after the HBView project was
established, pharmacists discovered two patients at risk
of HBV reactivation after the start of HBView project
who were not noticed beforehand (Table 2). In the first
case, a pharmacist discovered that the HBV screening re-
sult was missing. HBV reactivation may very well have
been prevented by the pharmacist’s quick action to rect-
ify the situation. In the second case, the patient was
found to have been HBsAg-positive at preoperative in-
spection after having started chemotherapy. Awareness
and recognition of HBV reactivation by the medical staff
at our hospital may have been low in days prior to the
introduction of the alert system. However, this case
was overlooked after the alert system was introduced,
probably because the system was not yet functioning ef-
fectively. The intervention of the pharmacists after the
HBView project was initiated may very well have pre-
vented HBV reactivation.
It is already recognized that HBV screening during
cancer chemotherapy is low [8–10]. However, this study
suggests that oversight can easily occur even if HBV
screening is performed. Furthermore, the study revealed
that there is a large risk associated with the failure to
notice and/or report positive HBV results. It was re-
ported that the proportion of HBsAg-positive patients
was 1.5 % and that of HBsAg-negative patients with
HBcAb and/or HBsAb-positivity was 23.2 % during in-
spection for HBV before blood transfusions [16]. It was
also reported that evidence of resolved hepatitis B
existed in 31.5 % of rheumatoid arthritis patients at
other facilities [17]. Therefore, it is suspected that HBV-
infected patients exist across many medical disciplines.
The risk of HBV reactivation underlies the cancer treat-
ment field and is of widespread concern, and must
therefore be adequately addressed. An interesting report
on HBV screening was published recently [18]. In that
report, a high compliance rate of adequate screening
and prophylactic therapy was achieved by introducing a
compulsive computerized order entry-based alert sys-
tem. However, the strength of such intervention by an
alert system is likely to be controversial in different insti-
tutions or regions.
Detailed information about the background and risk
factors of HBV reactivation is unknown. The JSH Guide-
lines for the Management of Hepatitis B Virus Infection
are as follows: “When immunosuppressive therapy or
chemotherapy is administered to HBsAg-positive in-
active carriers, or to patients with resolved HBV infec-
tion and HBV DNA levels of 2.1 log copies/mL on
pretreatment screening tests, nucleic acid analog therapy
should be commenced without delay” [5]. HBV reactiva-
tion is known to progress to fulminant hepatitis. Meas-
uring HBV DNA levels in the serum is useful for
determining the status of chronic HBV infection, as it
differentiates between active and inactive disease states.
On average, there are approximately 19 weeks between
the increase in HBV-DNA levels and the onset of
Table 2 The number of interventions concerning HBV reactivation by pharmacists
Pre-HBView Post-HBView P-value Analysis
(n = 5208) (n = 5228)
The number of interventions concerning
HBV reactivation
6 17 0.022 (1)
Pre-HBView Post-HBView P-value Analysis
(n = 6) (n = 17)
The number of initially unnoticed patients
discovered to be at risk for HBV reactivation
0 2 0.538 (2)
(1) Chi-squared test, (2) Fisher’s exact test. HBV, hepatitis B virus
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hepatitis [1]. This duration is the reason for the time
interval between the first and second message in the
alert system. The risk factors for HBV reactivation in-
clude the nature of treatment, such as hematopoietic
stem cell transplantation, organ transplantation, and
combination therapy of rituximab and corticosteroid or
systemic chemotherapy; and the status of HBsAg,
HBsAb, and/or HBcAb positivity [16]. Other risk factors
continue to be investigated [1, 2, 19–21]. Further investi-
gations will clarify additional therapeutic and prognostic
aspects of HBV reactivation.
Medication-use evaluation (MUE) has long been
regarded as important for improving medication-use
processes with the goal of optimal patient outcomes
[22]. The present study suggests that the MUE processes
conducted by pharmacists prevented medication-related
problems and improved patient safety. It is recom-
mended that pharmacists play a wider role in risk man-
agement during medical therapy. In the field of cancer
treatment, pharmacists manage medications, accept con-
sultations, and confirm that regimens are correct on a
daily basis. The HBView project highlighted the import-
ance of pharmacists with respect to HBV reactivation
prevention and is the type of endeavor that can both
clarify HBV reactivation consequences and improve out-
comes going forward.
Conclusions
Detection of patients at risk for HBV reactivation was
insufficient when using only an automatic alert system.
An additional system of verification and intervention by
pharmacists provided greater assurance of detecting
such patients.
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